Although vacancies are the best protection option before covid-19, monoclonal anticonvulsant therapies demonstrate potential as a ‘point’ that helps reduce covid-19 contagions and deaths. The results of various studies are revealed in these days and show them.
In the preliminary phases of the Phase III clinical trial conducted by Regeneron and the National Institutes of Allergy and Infectious Diseases and published in a press release this March, a combination therapy of two anticoagulants (casirivimab and imdevimab) reduce the risk of covid-19 contagion and prevent the development of syndromes in all patients who receive it (186 total of 400 participants).
The voluntary tenions have a high risk of contacting vivian puppies in hogares where algae have a positive effect on the covid-19 and the clinical trial is underway, with the goal of raising the 2,000 volunteers. The logarithmic laboratory adapts the administration of the treatment to that, by applying it by means of an injection by means of an intravenous infusion, thus facilitating the process.
Another study conducted by Eli Lilly’s laboratory found one 80% reduction in covid-19 contagios between senior residents and 60% in medical staff who receive a dose of the bamlanivimab anticonvulsant, compared to those who receive placebo.
Moving units with specialists capable of administering the antidote are immediately transmitted to seniors where a positive case of coronavirus is detected, as part of the investigation into whether the therapy helps prevent the contagios, so that it evaluates a total of 1,097 participants.
Eli Lilly’s other study in which 1,035 high-risk patients participated were diagnosed with covid-19, determined to have one 70% reduction in hospitalization and death risk to administer a combination of anticonvulsant therapy (bamlanivimab with etesevimab), which has not been approved by the FDA.
As a result, they are published exclusively in a press release and not in a scientific publication, the patients receiving the combination therapy will have a viral load and a rapid resolution of the symptoms.
The laboratory announces that there are also studies with variants like the one from South Africa for create other types of antikuerpos that can be effective against it and other types that emerge in the future, indicates the Bloomberg News Agency.
No vacancies (pero ayudan)
The antibodies are proteins that the body produces to defend pathogenic agents such as viruses or bacteria. The anticoagulant therapies son Concentrated versions of anticoagulants that have been extracted from patients with covid-19, copied and manufactured synthetically with mirrors that help prevent contagion or reduce the severity of the infection.
Different from the vacancies, then one day or two in order to generate an immune response – surten an immediate effect, pero a corto plazo.
“The vacancies are the most effective and the most expensive treatments, as long as they do not have to be as competent as the vacancies. It must be used for when it is very slow, when it has a broth and the people have it exposed and it will not be possible to hope that the vaccine will have an effect”, Explains the medical voice of Eli Lilly, Daniel Skovronsky in an interview with the New York Times.
Available, but only approved
The monoclonal anticoagulation therapies have only recently received FDA emergence treatment exclusively to prevent high-risk hospitalization with live covid-19 cases.
Paradoxically, the large-scale production of these monoclonal anticoagulants, which are difficult to produce on a scale, are the doses that have been distributed and have not been fully approved, CNN reports.
For more information about the use of anti-body therapies or how to access them, go to this official web page. The governing body distributes free of charge to patients, although it may have associated charges with its administration depending on the health center.